GlaxoSmithKline will acquire Genelabs Technologies for approximately $57 million in cash. This acquisition is part of GSK’s effort to develop new therapies for hepatitis C virus (HCV). Genelabs will become part of GSK’s Drug Discovery organization and its HCV programs will be consolidated into GSK’s therapeutic approaches already underway internally and through collaborations.     “Genelabs has demonstrated a strong track record in HCV drug discovery and identified numerous novel class...